The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Using dual-targeting CAR-Ts to overcome CAF-induced CAR-T resistance in multiple myeloma
Reona Sakemura, MD, PhD, Mayo Clinic, Rochester, MN, explains how we can overcome cancer-associated fibroblast (CAF)-induced CAR-T resistance using dual-targeting CAR-Ts in multiple myeloma. Whilst CAR-T therapy has shown remarkable efficacy, the durability of response is still limited. This has been attributed to the immunosuppressive tumor microenvironment, which is composed of several cells including CAFs. Pre-clinical experiments have shown that BCMA-directed CAR-Ts exhibit impaired function in multiple myeloma tumor microenvironment mouse models. Further experiments with dual-targeting CAR-Ts against BCMA and SLAMF7 showed improved anti-tumor efficacy and prolonged CAR-T persistence. These dual targeting CAR-Ts will be evaluated in a Phase I/II clinical trial in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
